Lifemd, Inc. Financials
This page shows Lifemd, Inc. (LFMDP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is finally outrunning overhead, but reported profit still depends on below-operating-line items rather than core earnings.
FY2025's7.4% net margin looks better than FY2024, but the core business still posted a-4.0% operating margin. That gap means the first profitable year was helped by below-operating-line items, so statutory earnings improved faster than the underlying operating engine.
The clearest operating shift is fixed-cost absorption: selling and administrative expense stayed near
The balance sheet also became materially less stretched: total liabilities fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Lifemd, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Lifemd, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Lifemd, Inc. generates $-0.74 in operating cash flow ($8.3M OCF vs -$11.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Lifemd, Inc. earns $-5.6 in operating income for every $1 of interest expense (-$7.7M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Lifemd, Inc. generated $194.1M in revenue in fiscal year 2025. This represents an increase of 25.3% from the prior year.
Lifemd, Inc.'s EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 66.3% from the prior year.
Lifemd, Inc. reported -$11.2M in net income in fiscal year 2025. This represents a decrease of 145.9% from the prior year.
Lifemd, Inc. earned $0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 141.7% from the prior year.
Cash & Balance Sheet
Lifemd, Inc. generated $6.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 60.1% from the prior year.
Lifemd, Inc. held $36.8M in cash against $0 in long-term debt as of fiscal year 2025.
Lifemd, Inc. had 47M shares outstanding in fiscal year 2025. This represents an increase of 10.6% from the prior year.
Margins & Returns
Lifemd, Inc.'s gross margin was 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.
Lifemd, Inc.'s operating margin was -4.0% in fiscal year 2025, reflecting core business profitability. This is up 9.2 percentage points from the prior year.
Lifemd, Inc.'s net profit margin was -5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.6 percentage points from the prior year.
Lifemd, Inc.'s ROE was -48.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Lifemd, Inc. spent $270K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Lifemd, Inc. invested $1.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.8% from the prior year.
LFMDP Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.2M+146.8% | $20.3M-66.2% | $60.2M-4.0% | $62.7M+23.2% | $50.9M+654.4% | $6.7M-87.3% | $53.3M+5.2% | $50.7M |
| Cost of Revenue | $5.9M+25.0% | $4.7M-36.0% | $7.4M-0.3% | $7.4M-8.7% | $8.1M+19.6% | $6.8M+35.7% | $5.0M-0.2% | $5.0M |
| Gross Profit | $44.2M+183.9% | $15.6M-70.5% | $52.8M-4.5% | $55.2M+29.2% | $42.8M+75774.3% | -$56K-100.1% | $48.3M+5.7% | $45.6M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $15.2M+60.7% | $9.4M-43.1% | $16.6M-5.6% | $17.6M+22.5% | $14.3M+138.8% | $6.0M-66.8% | $18.1M-2.2% | $18.5M |
| Operating Income | -$8.9M-119.5% | -$4.1M-106.5% | -$2.0M-336.1% | -$452K+61.8% | -$1.2M+69.9% | -$3.9M+1.7% | -$4.0M+36.6% | -$6.3M |
| Interest Expense | -$56K-100.6% | -$28K-110.7% | $262K-60.4% | $663K+43.0% | $464K-23.7% | $608K+8.8% | $559K+5.1% | $531K |
| Income Tax | N/A | N/A | $169K | N/A | N/A | N/A | $233K | N/A |
| Net Income | -$8.9M-57.4% | -$5.6M-48.1% | -$3.8M-135.0% | -$1.6M-781.3% | -$184K-100.4% | $42.8M+1019.2% | -$4.7M+32.3% | -$6.9M |
| EPS (Diluted) | $-0.20 | N/A | $-0.10-100.0% | $-0.05-150.0% | $-0.02 | N/A | $-0.13+31.6% | $-0.19 |
LFMDP Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $70.1M-0.4% | $70.4M+6.7% | $66.0M-10.3% | $73.6M-0.1% | $73.6M-3.3% | $76.1M+4.9% | $72.6M+13.7% | $63.8M |
| Current Assets | $51.7M-0.3% | $51.8M+26.2% | $41.1M-16.2% | $49.0M-1.9% | $50.0M-4.6% | $52.4M+7.6% | $48.7M+8.0% | $45.1M |
| Cash & Equivalents | $34.5M-6.3% | $36.8M+54.7% | $23.8M-34.3% | $36.2M+5.3% | $34.4M-1.7% | $35.0M-6.9% | $37.6M+5.3% | $35.7M |
| Inventory | $3.2M+14.6% | $2.8M-19.2% | $3.4M+5.6% | $3.3M+9.6% | $3.0M+6.1% | $2.8M+5.7% | $2.6M+28.4% | $2.1M |
| Accounts Receivable | $9.9M+5.9% | $9.3M+0.7% | $9.2M+26.1% | $7.3M-28.1% | $10.2M-2.5% | $10.5M+72.8% | $6.0M+6.7% | $5.7M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $55.1M+16.6% | $47.3M-24.5% | $62.6M-14.4% | $73.2M-1.1% | $74.0M-11.5% | $83.7M+6.5% | $78.5M+19.2% | $65.9M |
| Current Liabilities | $49.6M+19.3% | $41.6M-26.6% | $56.7M-10.8% | $63.5M+4.3% | $60.9M-9.6% | $67.4M+14.3% | $59.0M+14.1% | $51.6M |
| Long-Term Debt | N/A | N/A | N/A | $15.9M | N/A | N/A | N/A | N/A |
| Total Equity | $15.0M-35.1% | $23.2M+1661.8% | $1.3M+173.7% | -$1.8M+23.5% | -$2.3M+74.4% | -$9.1M-17.7% | -$7.7M-83.5% | -$4.2M |
| Retained Earnings | -$238.3M-4.2% | -$228.6M+7.7% | -$247.8M-3.9% | -$238.5M-1.2% | -$235.6M+1.8% | -$239.9M-1.9% | -$235.4M-2.6% | -$229.5M |
LFMDP Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $445K+113.6% | -$3.3M-2129.6% | -$147K-101.7% | $8.6M+181.6% | $3.1M+185.9% | $1.1M-84.0% | $6.7M+47.5% | $4.5M |
| Capital Expenditures | $105K-32.3% | $155K-80.5% | $797K-0.4% | $800K+580.9% | $118K-40.6% | $198K-55.8% | $448K-30.3% | $642K |
| Free Cash Flow | $339K+109.9% | -$3.4M-263.8% | -$944K-112.0% | $7.8M+165.7% | $3.0M+237.1% | $875K-86.0% | $6.3M+60.4% | $3.9M |
| Investing Cash Flow | -$2.1M-112.0% | $17.1M+574.9% | -$3.6M+2.8% | -$3.7M-29.0% | -$2.9M-5.4% | -$2.7M+22.1% | -$3.5M-11.5% | -$3.1M |
| Financing Cash Flow | -$696K+11.7% | -$789K+90.9% | -$8.7M-180.2% | -$3.1M-282.1% | -$813K+13.1% | -$935K+29.2% | -$1.3M-62.0% | -$815K |
| Dividends Paid | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K |
| Share Buybacks | N/A | N/A | $270K | N/A | N/A | N/A | N/A | N/A |
LFMDP Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.2%+11.5pp | 76.7%-11.0pp | 87.7%-0.4pp | 88.1%+4.1pp | 84.0%+84.8pp | -0.8%-91.4pp | 90.6%+0.5pp | 90.1% |
| Operating Margin | -17.8%+2.2pp | -20.0%-16.7pp | -3.3%-2.6pp | -0.7%+1.6pp | -2.3%+55.9pp | -58.2%-50.7pp | -7.5%+5.0pp | -12.4% |
| Net Margin | -17.7%+10.1pp | -27.8%-21.4pp | -6.3%-3.7pp | -2.6%-2.2pp | -0.4%-635.1pp | 634.7%+643.5pp | -8.7%+4.8pp | -13.6% |
| Return on Equity | -59.0%-145.2pp | 86.2%+375.8pp | -289.6% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.7%-4.6pp | -8.0%-2.2pp | -5.8%-3.6pp | -2.2%-1.9pp | -0.3%-56.5pp | 56.3%+62.7pp | -6.4%+4.4pp | -10.8% |
| Current Ratio | 1.04-0.2 | 1.25+0.5 | 0.73-0.0 | 0.77-0.0 | 0.82+0.0 | 0.78-0.0 | 0.83-0.0 | 0.87 |
| Debt-to-Equity | 3.66+1.6 | 2.04-45.6 | 47.64+56.6 | -8.92+22.9 | -31.78-22.6 | -9.21+1.0 | -10.17+5.5 | -15.66 |
| FCF Margin | 0.7%+17.6pp | -16.9%-15.3pp | -1.6%-14.1pp | 12.5%+6.7pp | 5.8%-7.2pp | 13.0%+1.2pp | 11.7%+4.0pp | 7.7% |
Similar Companies
Frequently Asked Questions
What is Lifemd, Inc.'s annual revenue?
Lifemd, Inc. (LFMDP) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lifemd, Inc.'s revenue growing?
Lifemd, Inc. (LFMDP) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.
Is Lifemd, Inc. profitable?
No, Lifemd, Inc. (LFMDP) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -5.8%.
What is Lifemd, Inc.'s EBITDA?
Lifemd, Inc. (LFMDP) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lifemd, Inc.'s gross margin?
Lifemd, Inc. (LFMDP) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Lifemd, Inc.'s operating margin?
Lifemd, Inc. (LFMDP) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Lifemd, Inc.'s net profit margin?
Lifemd, Inc. (LFMDP) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Lifemd, Inc.'s return on equity (ROE)?
Lifemd, Inc. (LFMDP) has a return on equity of -48.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Lifemd, Inc.'s free cash flow?
Lifemd, Inc. (LFMDP) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lifemd, Inc.'s operating cash flow?
Lifemd, Inc. (LFMDP) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Lifemd, Inc.'s total assets?
Lifemd, Inc. (LFMDP) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lifemd, Inc.'s capital expenditures?
Lifemd, Inc. (LFMDP) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Lifemd, Inc.'s current ratio?
Lifemd, Inc. (LFMDP) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.
What is Lifemd, Inc.'s debt-to-equity ratio?
Lifemd, Inc. (LFMDP) had a debt-to-equity ratio of 2.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lifemd, Inc.'s return on assets (ROA)?
Lifemd, Inc. (LFMDP) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lifemd, Inc.'s Piotroski F-Score?
Lifemd, Inc. (LFMDP) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lifemd, Inc.'s earnings high quality?
Lifemd, Inc. (LFMDP) has an earnings quality ratio of -0.74x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Lifemd, Inc. cover its interest payments?
Lifemd, Inc. (LFMDP) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Lifemd, Inc.?
Lifemd, Inc. (LFMDP) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.